Practical considerations in the use of apomorphine injectable

Neurology

Volumn 62, Issue 6 SUPPL. 4, 2004, Pages

  Bowron, Annette ^a  

^a NORTH TYNESIDE GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; APOMORPHINE;

BEHAVIOR DISORDER; CAREGIVER; CONFUSION; DOSE RESPONSE; DRUG USE; DYSKINESIA; HALLUCINATION; HUMAN; NAUSEA; ON OFF PHENOMENON; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATIENT COUNSELING; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN NODULE; SOMNOLENCE; SYMPTOMATOLOGY; TITRIMETRY;

EID: 1842575713     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.62.6_suppl_4.s32     Document Type: Review

References (36)

1. Schwab RS, Amador LV, Lettvin JY. Apomorphine in Parkinson's disease. Trans Am Neurol Assoc 1951;76:251-253.
2. Cotzias GC, Papavasiliou PS, Tolosa ES, Mendez JS, Bell-Midura M. Treatment of Parkinson's disease with aporphines. Possible role of growth hormone. N Engl J Med 1976;294:567-572.
3. Corsini GU, Del Zompo M, Gessa GL, Mangoni A. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease. Lancet 1979;1:954-956.
4. Schwab RS, Amador LV, Lettvin JY. Apomorphine in Parkinson's disease. Trans Am Neurol Assoc 1951;76:251-253.
5. Stibe CM, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988;1:403-406.
6. Hutton JT, Dewey RB Jr, LeWitt PA, Factor SA. A randomized, double blind, placebo-controlled trial of subcutaneously-injected apomorphine for parkinsonian "off" states. Mov Disord 2000;15(suppl 3):130. Abstract.
7. Ostergaard L, Werdelin L, Odin P, et al. Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995;58:681-687.
8. Merello M, Pikielny R, Cammarota A, Leiguarda R. Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study. Clin Neuropharmacol 1997;20:165-167.
9. van Laar T, Jansen EN, Essink AW, Neef C, Oosterloo S, Roos RA. A double-blind study of the efficacy of apomorphine and its assessment in "off"-periods in Parkinson's disease. Clin Neurol Neurosurg 1993;95: 231-235.
10. Lees AJ. Dopamine agonists in Parkinson's disease: a look at apomorphine. Fund Clin Pharmacol 1993;7:121-128.
11. Parkinson's Disease Society. Meeting a need? The role of the Parkinson's Disease Nurse Specialist. London: Parkinson's Disease Society, 1994.
12. Calne S. Nursing care of patients with idiopathic parkinsonism. Nurs Times 1994;90:38-39.
13. Lees AJ, Turner K, Richardson C. Treatment of Parkinson's disease with apomorphine - Shared Care Guidelines. 3rd ed. University College London Hospitals NHS Trust, 1999.
14. Hagell P, Odin P. Apomorphine in the treatment of Parkinson's disease. J Neurosci Nurs 2001;33:21-34, 37-38. Review.
15. Shared Care Guidelines 2002. Chaudhuri KR, Clough C, Blockley A. The use of apomorphine in Parkinson's disease. 1st ed. King's College Hospital NHS Trust, 2001.
16. O'Sullivan JD, Lees AJ. Use of apomorphine in Parkinson's disease. Hosp Med 1999;60:816-820.
17. MacMahon DG. Use of apomorphine in clinical practice. Adv Neurol 1999;80:529-533.
18. Fahn S, Elton RL, and the UPDRS Development Committee. The Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, eds. Recent developments in Parkinson's disease. New York: Mac-Millan, 1987:153-163.
19. Gasser T, Schwarz J, Arnold G, Trenkwalder C, Oertel WH. Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease. Arch Neurol 1992;49:1131-1134.
20. Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 1993;8:165-170.
21. Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J Neurol Neurosurg Psychiatry 1998;65:709-716.
22. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long-term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998;64:573-576.
23. Duby SE, Cotzias GC, Papavasiliou PS, Lawrence WH. Injected apomorphine and orally administered levodopa in parkinsonism. Arch Neurol 1972;27:474-480.
24. Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67:492-496.
25. Chaudhuri KR, Clough C. Subcutaneous apomorphine in Parkinson's disease. BMJ 1998;316:641.
26. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999;52:1908-1910.
27. Homann CN, Wenzel K, Suppan K, et al. Sleep attacks in patients taking dopamine agonists. BMJ 2002;324:1483-1487. Review.
28. Olanow CW, Schapira AH, Roth T. Waking up to sleep episodes in Parkinson's disease. Mov Disord 2000;15:212-215.
29. Lachenmayer L. Parkinson's disease and the ability to drive. J Neurol 2000;247(suppl 4):IV/28-30.
30. Frucht SJ, Greene PE, Fahn S. Sleep episodes in Parkinson's disease: a wake-up call. Mov Disord 2000;15:601-603.
31. Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 1993;8:165-170.
32. Wenning GK, Bosch S, Luginger E, Wagner M, Poewe W. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease. Adv Neurol 1999;80: 545-548.
33. Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001;58:1385-1392.
34. Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:96-101.
35. Poewe W, Kleedorfer B, Wagner M, Bosch S, Schelosky L. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients. Adv Neurol 1993;60: 656-659.
36. McGee P. Apomorphine treatment: a nurse's perspective. Adv Clin Neurosci Rehab 2002;2:23-24.